# Probiotic effect of trichloroacetic acid on cervicovaginal microbiota in cervical intraepithelial neoplasia: A pilot study

<sup>5</sup> Takeo Shibata<sup>1</sup>, Ayumu Ohno<sup>2,5,6</sup>, Isao Murakami<sup>3</sup>, Masahiro Takakura<sup>1</sup>, Toshiyuki

6 Sasagawa<sup>1\*</sup>, Tadashi Imanishi<sup>2</sup>, Mikio Mikami<sup>4</sup>

<sup>1</sup> Department of Obstetrics and Gynecology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa, Japan ; <sup>2</sup> Department of Molecular Life Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan ; <sup>3</sup> Department of 9 Obstetrics and Gynecology, Toho University Ohashi Medical Center, 2-22-36 Ohashi, 10 Meguro, Tokyo, Japan ; <sup>4</sup> Department of Obstetrics and Gynecology, Tokai University 11 School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan ; <sup>5</sup> Graduate School of 12 Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1 13 Tsushima-naka, Kita-ku, Okayama, Okayama, Japan ; <sup>6</sup> Collaborative Research Centre of 14 Okayama University for Infectious Diseases in India at ICMR-NICED, 57 Dr. SC Banerjee 15

- <sup>16</sup> Road, Beliaghata Kolkata, India
- <sup>18</sup> **Abstract** Symbiosis of bacteria and human papillomavirus (HPV) in the cervicovaginal
- <sup>19</sup> environment influences cervical intraepithelial neoplasia (CIN) progression or regression. In this
- 20 case series, we enrolled all 10 patients who had resolved CIN after a cervical local treatment using
- <sup>21</sup> trichloroacetic acid (TCA). Prominent changes in the cervicovaginal microbiota, such as an
- <sup>22</sup> enrichment of the genus *Bifidobacterium* and genus *Lactobacillus*, were observed in seven of 10
- patients. A decrease in cervicovaginal bacterial alpha diversity was observed in 4 patients with
- <sup>24</sup> high-risk HPV clearance. Differential abundance analysis revealed that genus *Bifidobacterium*
- <sup>25</sup> increased significantly after TCA. The dominance of a single bacteria can be characteristic of CIN
- <sup>26</sup> cures after TCA. These results highlight the potential link of cervicovaginal bacteria such as genus
- 27 Bifidobacterium and genus Lactobacillus in the clearance of CIN and high-risk HPV. This pilot study
- <sup>28</sup> guides future research questions that specific cervicovaginal bacteria may be promising candidates
- <sup>29</sup> for probiotic therapy to treat CIN and HPV infections.
- 30

17

- <sup>31</sup> Introduction
- About 5% of all cancers are attributed to human papillomavirus (HPV) infection Forman et al. (2012).
- <sup>33</sup> HPV infects mucous membranes and causes a variety of diseases such as genital warts, precancerous
- <sup>34</sup> cervical lesions (cervical intraepithelial neoplasia: CIN), cervical cancer, vaginal intra-epithelial
- <sup>35</sup> neoplasia (VAIN), vaginal cancer, vulvar cancer, penile cancer, anal cancer, head and neck cancer,
- <sup>36</sup> and even recurrent respiratory papillomatosis throughout the body **Doorbar et al. (2015)WHO (2021).**
- <sup>37</sup> HPVs are classified into more than 200 genotypes, some HPVs are categorized based on the risk of
- developing cancer, such as high-risk HPV (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,

### \*For correspondence:

tsasa@kanazawa-med.ac.jp (TS)

**Present address:** <sup>\*</sup>Department of Obstetrics and Gynecology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan

- and 68)Doorbar et al. (2012)Hum (2021b). Especially, HPV type 16 or HPV type 18 causes 70% of 39
- cervical cancers and CINHum (2021g). The development of HPV-related diseases, namely CIN and 40
- cervical cancer, has been elucidated in considerable detail in molecular biology Doorbar et al. (2012). 41
- E6 and E7 proteins as viral oncogenes and proteins are key to carcinogenesis. They modulate the
  - activity of p53 and retinoblastoma family proteins **Doorbar et al.** (2012).
- The factors that influence the progression or regression of CIN are unknown, however, HPV 44 is the evident cause of CINSasagawa et al. (1992) and cervical cancer Pal and Kundu (2020) HPV 45
- infection is a common infection that affects more than half of the cases within 5 years of the onset 46
- of sexual intercourse *Winer et al.* (2003). However, the incidence of cancer is low compared to 47
- the infection rate of HPV*Winer et al.* (2003). Evidence suggests an association between symbiotic 18
- bacteria in humans and carcinogenesis **Doocev et al.** (2022). The cervicovaginal bacterial community 49
- have been shown to be associated with the progression or elimination of CIN or HPV infection *Mitra* 50
- et al. (2016) Kyrgiou et al. (2017) Norenhag et al. (2020) Lin et al. (2020) Cheng et al. (2020) Usyk et al. 51 (2020). As a feature of cervical or vaginal microbiome (cervicovaginal microbiome), Lactobacillus are
- 52 dominant, however, non-lactobacillus-dominance or lactobacillus iners are dominant in the patients 53
- with CIN or high-risk HPV positiveNorenhag et al. (2020)Lin et al. (2020). Non-Lactobacillus-dominant 54
- environment such as bacterial vaginosis (BV) was associated with higher rates of HPV infection, high-55
- risk HPV persistence, and delayed HPV clearance *Kyrgiou et al.* (2017). In particular, cervicovaginal 56
- bacterial composition under HPV infection was characterized by BV-associated bacteria, which is an 57
- anaerobic bacteria such as Sneathia, Prevotella, and MegasphaeraCheng et al. (2020). In addition. 58
- Gardnerella-enrichment is associated with developing high-grade squamous intraepithelial lesion 50
- (HSIL) in a longitudinal study Usyk et al. (2020). Multiple HPV infections compared to no HPV 60 infections were attributed to the increased bacterial biodiversity (i.e., high alpha diversity) Cheng
- 61 et al. (2020). 62
- A classic excision procedure called cervical conization for CIN, which removes the cervix, has 63 been reported to increase Obstetric adverse events such as preterm birth and premature rupture 64 of membranes Bevis and Biggio (2011). To develop minimally invasive treatment, we conducted 65 clinical trials for trichloroacetic acid (TCA) or phenol treatment on the CIN or VAIN lesions Maehama 66
- et al. (2023). In phenol-treated patients, disease regression rates after 24 months for CIN1-3 67 were 99%, 98%, and 100%, respectively *Machana et al.* (2023). We observed that most patients 68
- resolved CIN or VAIN lesions upon TCA application within one year (in preparation). This chemical 60
- peeling method presumes to remove the epithelial lesions of such HPV-related diseases. The host 70
- immune responses are likely to be involved with the complete clearance of diseases by this method. 71
- TCA treatment can potentially avoid cervical conization and hysterectomy and is a more desirable 72
- treatment for women who wish to bear children in the future. 73
- We hypothesize that cervicovaginal bacterial dynamics are involved with the clearance of CIN and 74 HPV infection after TCA treatment. In this pilot study, we investigated the difference in cervicovaginal 75 bacteria before and after chemical peeling treatment by TCA in patients who had cleared not only
- 76 CIN/VAIN but also high-risk HPV with TCA treatment. We attempt to identify bacteria that are 77
- candidates for probiotic treatment to establish safe and effective invasive treatment for CIN or 78 VAIN. 79
- Results

80

43

### Patient characteristics and clearance of HPV 81

- The average age of patients enrolled in this pilot study was  $35.7 \pm 8.1$  years old (10 patients). The 82
- average TCA treatment duration of patients with CIN or VAIN lesions from initial sample collection to 83
- eventual cure was 289 days. The 10 patients with CIN (nine patients: one CIN1: two CIN2: six CIN3) or 84
- VAIN (one patient, VAIN2) diagnosed by colposcopy and biopsy were enrolled in this analysis (Table 85
- 1). The distribution of race or ethnicity was 100% Japanese. In pre-TCA treatment phase, cervical 86
- cytology was; atypical glandular cells: AGC (n = 1), adenocarcinoma in situ: AIS (n = 1), atypical 87

- squamous cells of undetermined significance: ASCUS (n = 1), high grade squamous intraepithelial
- <sup>89</sup> lesion: HSIL (n = 4), and low grade squamous intraepithelial lesion: LSIL (n = 3). High-risk HPV was
- 90% positive before TCA treatment and 60% after TCA treatment (Table 1). However, at follow-up
- <sup>91</sup> after TCA treatment we observed that high-risk HPV disappeared in all patients within 9 months (Table 2).

Test	Diagnosis	Number of Patients	Frequency (%)
Before Treatment			
Cytology	AGC	1	10
	AIS	1	10
	ASCUS	1	10
	HSIL	4	40
	LSIL	3	30
Biopsy	CIN1	1	10
	CIN2	2	20
	CIN3	6	60
	VAIN2	1	10
High-risk HPV*	Negative	1	10
	Positive	9	90
After Treatment			
Cytology	NILM	10	100
High-risk HPV*	Negative	4	40
	Positive	6	60

Table 1. Patient Characteristics.

\*: Total 14 high-risk HPV genotypes were defined as HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. AGC: atypical glandular cells; AIS: adenocarcinoma in situ; ASUCUS: atypical squamous cells of undetermined significance; HSIL: high grade squamous intraepithelial lesion; LSIL: low grade squamous intraepithelial lesion; CIN: cervical intraepithelial neoplasia; VAIN: vaginal intraepithelial neoplasia; HPV: human papillomavirus; NILM: negative for intraepithelial lesion or malignancy.

92

### 93 Statistics of reads and taxa

94 After importing 20 raw fastq files, we obtained a total of 1,812,889 reads, mean 90644.4 reads,

median 83714.5 reads, minimum 6658 reads, and maximum 191,622 reads. After final quality

- <sup>96</sup> filtering using q2-dada2 and q2-quality-control, we obtained 494 features (taxa) and a total of
- 97 714,869 features (taxa) in 20 samples. For read-length, the minimum length was 38, maximum
- <sup>98</sup> length 283, and mean length 236.96.

### <sup>99</sup> Characteristics of cervicovaginal microbiota pre- or post- TCA treatment

Among the identified bacteria, the top genera before and after TCA treatment are shown in Figure
 1A. These top bacteria are mentioned below based on their frequency (%).

- 1. Genus *Lactobacillus*, after TCA, 38.9%
- <sup>103</sup> 2. Genus *Lactobacillus*, before TCA, 37.3%
- <sup>104</sup> 3. Genus *Gardnerella*, before TCA, 21.9%
- 105 4. Genus *Bifidobacterium*, after TCA, 16.4%
- <sup>106</sup> 5. Genus *Prevotella*, before TCA, 12.9%
- 107 6. Genus *Gardnerella*, after TCA, 11.4%
- <sup>108</sup> 7. Genus *Prevotella*, after TCA, 11.1%

### Table 2. Clearance of HPV after TCA treatment.

Cases	Diagnosis	HPV Before TCA	HPV After TCA	HPV at Follow-up After TCA
Case 01	CIN3	52	67	Not examined*
Case 02	CIN3	16	66	Negative
Case 03	CIN2	6, 16, 53, 54, 58, 66	Negative	Negative
Case 04	CIN2	31	31, 51	Negative
Case 05	CIN1	51, 82	Negative	Not examined*
Case 06	VAIN2	6, 62, 81	59	Negative
Case 07	CIN3	16, 51, 56, 59, 66, 70	59	Negative
Case 08	CIN3	16	52, 67	Negative
Case 09	CIN3	16, 52	58	Negative
Case 10	CIN3	16, 31	Negative	Not examined*

\*: No HPV typing was done at the time of follow-up for patients who were negative for high-risk HPV after TCA treatment. HPV: human papillomavirus; TCA: trichloroacetic acid; CIN: cervical intraepithelial neoplasia; VAIN: vaginal intraepithelial neoplasia.


- 109 8. Genus *Megasphaera*, before TCA, 7.14%
- 9. Genus *Atopobium*, before TCA, 6.87%
- 111 10. Genus *Atopobium*, after TCA, 4.19%


112 11. Genus *Megasphaera*, after TCA, 3.64%


The frequency of the top bacteria, except for genus *Bifidobacterium* did not largely change before 113 and after TCA treatment, for example, genera Lactobacillus (37.3% before vs. 38.9% after TCA 114 treatment), Gardnerella (21.9% before vs. 11.4% after TCA treatment), Prevotella (12.9% before 115 vs. 11.1% after TCA treatment), Atopobium (6.87% before vs. 4.19% after TCA treatment), and 116 Megasphaera (7.14% before vs. 3.64% after TCA treatment). Contrarily, the genus Bifidobacterium 117 changed significantly before and after TCA treatment; the frequency increased from 1% before TCA 118 treatment to 16.4% after TCA treatment. Figure 1B shows the change in the cervicovaginal bacterial 119 microbiota before and after TCA treatment for each patient. Figure 1B provides information on high-120 risk HPV clearance and persistence after TCA treatment. An enrichment of genus Bifidobacterium 121 and genus Lactobacillus were observed in seven of 10 patients (Cases 01, 03, 04, 05, 06, 09, and 122 10) after TCA treatment. We found that genus Bifidobacterium (blue bar) increased in two patients 123 (Cases 05 and 09) after TCA treatment. As an additional finding, in four patients (Cases 01, 03, 04, 124 and 06), cervicovaginal bacterial microbiota was dominated primarily by the genus Lactobacillus 125 (green bar, 99.9%, 100%, 98.2%, and 72.0%, respectively) after TCA treatment. 126

### 127 Alpha and beta diversity analyses


Decline in alpha diversity was observed in seven of 10 patients (Cases 01, 03, 05, 06, 07, 09, and 10. 128 Figure 2). Alpha diversity was consistently decreased in four patients with high-risk HPV clearance 129 after TCA treatment (Cases 01, 03, 05, and 10, top panel of Figure 2). Both decreased alpha diversity 130 (three patients, Cases 06, 07, and 09) and increased (three patients, Cases 02, 04, and 08) were 131 observed in patients with high-risk HPV persistence after TCA treatment (bottom panel of Figure 2). 132 We examined whether the cervicovaginal bacterial microbiota is affected by factors including: 133 factor 1: individuals, factor 2: pre- or post-TCA treatment, and factor 3: high-risk HPV. Individual 134 differences, not TCA treatment or high-risk HPV, define the similarity of bacterial composition in the 135 cervicovaginal bacterial microbiota (Figure 3). About 50.9% of microbial variation could be explained 136 by patient differences (R2 = 0.509, p = 0.030, Adonis test, Figure 3A), High-risk HPV infection before 137 TCA treatment explained 6.8% variation of microbe composition (R2 = 0.068, p = 0.149, Adonis 138 test, Figure 3C). High-risk HPV infection after TCA treatment explained 6.7% variation of microbe 139 composition (R2 = 0.067, p = 0.131, Adonis test, Figure 3D). Before and after chemical peeling using 140







TCA explained only 3.6% variation of microbe composition (R2 = 0.036, p = 0.408, Adonis test, Figure 3B).



# Differential abundance analysis for cervicovaginal microbiota between pre- and post-TCA


There was a remarkable increase in genus Bifidobacterium in Cases 05 and 09 after TCA treatment, 145 as shown in the bar graphs (Figure 1B). Consistent with this result at the genus level, we observed 146 an increase in one *Bifidobacterium sp.* after TCA treatment, although we were unable to identify 147 the species due to the resolution limitation of 16S rRNA analysis (log fold-change: -25.0, adjusted 148 p-value < 0.001, Figure 4). Results for the genus Lactobacillus and Lactobacillus sp. were inconsistent 149 between pre- and post-TCA treatment. Thus, some Lactobacillus species were enriched after TCA 150 treatment, while others were before TCA treatment. The Lactobacillus sp. enriched before TCA 151 treatment were not identified due to the resolution limitation of 16S rRNA analysis (log fold-change: 152 23.1, adjusted p-value < 0.001, Figure 4). 153

### 154 Discussion


166


Nonsurgical treatment of CIN should be especially considered for women of childbearing age. The 155 effectiveness of TCA treatment for CIN has been analyzed not only by us but also by multiple research 156 groups, and it may become a standard treatment for CIN in the futureSchwameis et al. (2022). 157 However, there is a lack of data regarding the healing mechanism of CIN after TCA treatment. As 158 represented in Döderlein's bacillus described by Dr. Albert Döderlein, a relatively simple composition 159 of bacteria such as Lactobacillus in the vagina is healthy. Persistent HPV infection increases the risk 160 of developing cervical cancer and CIN: however, it is unclear what type of cervicovaginal bacteria 161 are involved in the disappearance of CIN. This research is an attempt to analyze the relationship 162 between cervicovaginal microbiota, high-risk-HPV, and the regression of CIN. 163 In this study, the mean duration required for the clearance of CIN or VAIN lesions after TCA 164 administration was 289 days. After nearly a year of long-term follow-up along with high risk-HPV 165

disappearance, it was observed that the cervicovaginal microbiota in CIN/VAIN-cured patients



**Figure 3. Principal component analysis (beta diversity) by patients, TCA treatment, and high-risk HPV.** Samples are predominately clustered by (A) individuals. Samples are not clustered by (B) pre- or post-TCA treatment, (C) high-risk HPV infection before TCA treatment, and (D) high-risk HPV infection after TCA treatment. A: Samples are colored with 10 kinds of color for each patient. B: Samples are colored by after TCA treatment (red, diamond) and before TCA treatment (blue, circle). C: Samples before TCA treatment are colored by high-risk HPV positive (green, circle) and negative (purple, diamond). D: Samples after TCA treatment are colored by high-risk HPV positive (green, circle) and negative (purple, diamond). About 50.9% of microbial variation could be explained by patient differences (R2 = 0.509, p = 0.030, Adonis test, A). Before and after chemical peeling using TCA explained only 3.6% variation of microbe composition (R2 = 0.036, p = 0.408, Adonis test, B). High-risk HPV infection before TCA treatment explained 6.8% variation of microbe composition (R2 = 0.068, p = 0.149, Adonis test, C). High-risk HPV infection after TCA treatment explained 6.7% variation of microbe composition (R2 = 0.067, p = 0.131, Adonis test, D).





changed into an environment dominated largely by a single bacteria such as genus Lactobacillus 167 or Bifidobacterium (Figure 1). Then, BV-associated bacteria such genera Gardnerella, Prevotella, 168 Atopobium, and Megasphaera were decreased after TCA treatment (Figure 1). A simplification of 160 the bacterial composition, suggested by a decrease in alpha diversity was observed in all patients 170 with all CIN clearance and high-risk HPV negative, whereas an increase in alpha diversity was seen 171 in patients with persistent HPV, suggesting that the cervicovaginal microbiome may influence the 172 action of high-risk HPV elimination (Figure 2). The enrichment of Bifidobacterium sp. after TCA 173 treatment in the patients with CIN or VAIN clearance is enough to be detected by differential 17/ abundance analysis, suggesting that the transformation into a single microbiota in the cervix and 175 vagina, not only by Lactobacillus but also by Bifidobacterium may be the key to clearance of CIN 176 or VAIN lesions (Figure 4). Taken together, this study infers the natural history of CIN clearance 177 processes with TCA treatment associated with high-risk-HPV and the cervicovaginal microbiome. 178 Thus, below is a possible mechanism by which TCA treats CIN: TCA first causes detachment of the 179 CIN/VAIN lesion (phase I), changes in the cervicovaginal microbiome (phase II, increase in genera 180 Lactobacillus and Bifidobacterium and decrease in BV-associated bacteria), clearance of high-risk-HPV 181 (phase III). 182 We should be cautious about whether *Bifidobacterium* could be a candidate for probiotic treat-183

ment of CIN and HPV infections. However, previous studies suggest that *Bifidobacterium* is a useful 184 bacterium against HPV infection. Mei et al. reported that Bifidobacterium were enriched in the 185 patients with clearance of HPV 16 compared to patients with no history of high risk-HPV infection Mei 186 et al. (2022). Similarly, this phenomenon was observed in Case 09 (i.e., HPV16 was negative at 187 follow-up after TCA treatment). Cha et al. reported the probiotic effect of *Bifidobacterium* on SiHa 188 cervical cancer cell line expressing HPV 16 and found the suppression of E6 and E7Cha et al. (2012). 189 Further investigation is needed to decipher the relationship between *Bifidobacterium* and CIN and 190 HPV persistent/clearance. 191

When discussing whether Lactobacilli affects the clearance of CIN and HPV. we should discuss it 192 at the species level rather than the genus level. Ou et al. reported the effects of oral administration 193 of Lactobacillus rhamnosus and Lactobacillus reuteri on HPV clearance and cervical cytology: rate 194 of ASCUS and LSIL dropped from 21.0% to 6.5% in probiotic group vs 15.3% to 10.2% in control 195 group, p = 0.017*Ou et al. (2019)*. According to Nicolò et al., Lactobacillus gasseri or Lactobacillus 196 *iensenii* induce interferon-y and these species may have the potential to assist immune cells with 197 HPV clearanceNicolò et al. (2021). On the contrary. Brotman et al. showed that Lactobacillus iners 198 had relatively higher proportion of HPV-positive samples, suggesting their link with the risk of HPV 190 persistence Brotman et al. (2014). In this study, an increase in genus Lactobacillus was observed after 200 CIN cure (Figure 1), but upon differential abundance analysis, Lactobacillus sp. decreased (Figure 201 4). That is, some Lactobacillus spp. increased before TCA treatment, while other Lactobacillus spp. 202 decreased after TCA treatment. Analysis using long reads is necessary to identify the abundance at 203

204 species level.

However, there are certain limitations of this study. In this case series, we analyzed only 10 205 patients with cured CIN, with emphasis on the homogeneity of the patient background. It is difficult 206 to draw general conclusions from case series, therefore, in the next project that expands on this 207 research, we plan to conduct a case-control study and time-series analysis of a large number of 208 healthy women as well as CIN patients receiving TCA treatment. Their use in probiotic therapies for 209 CIN require detailed basic microbiological studies and prospective clinical trials that were beyond 210 the scope of this study. A clear understanding of the interplay between several factors, including 211 oncogenic HPV, humans, bacteria, and possibly a fungus in order to control probiotic treatment 212 that manipulates the composition of cervicovaginal bacteria is necessary. 213

The cervicovaginal microbiome is an important factor in the clearance of CIN and HPV. Low inva-214 sive local treatment with chemical peels using TCA may be associated with changes in Lactobacillus or 215 *Bifidobacterium* in the cervicovaginal microbiota. This pilot study leads to the hypothesis that certain 216 bacteria that fluctuate in the cervicovaginal ecology are promising as they may be prospective 217 candidates for probiotic treatment to treat CIN and HPV infection. We advocate the importance of 218 CIN management in order to understand not only the state of oncogenic HPV infection but also 219 the cervicovaginal microbiome. Further intensive research in metabolome or immunity research is 220 needed to examine both the role of the cervicovaginal microbiota in cancer and the use of probiotics 221

<sup>222</sup> for cancer treatment.

### 223 Methods and Materials

### 224 Ethics approval

<sup>225</sup> This study was approved by the Institutional Review Board at the Kanazawa Medical University (IRB

<sup>226</sup> #I322). Written informed consent was obtained from all study patients.

### 227 Patient selection and chemical peeling treatment with TCA for CIN and VAIN

Fligible patients who met the following conditions were selected for this pilot study: 1: Patients 228 treated by TCA at Kanazawa Medical University during the period from 2017 to 2020; 2: A cytology 220 specimen prior to TCA treatment was archived: 3: All patients were those who were cleared with 230 CIN or VAIN after TCA treatment. Under the above selection conditions, 14 patients were treated 231 with TCA. 12 patients had samples available, and 10 patients with cured CIN or VAIN lesions were 232 included in the analysis. All 10 patients were diagnosed with CIN or VAIN using the punch biopsy 233 specimens under the guidance of colposcopy. No patients have undergone a hysterectomy or loop 234 electrosurgical excision procedure (LEEP) before or after TCA treatment. TCA (70%) was applied to 235 wide areas of the cervical or vaginal lesions three to five times using a small cotton tip every 4 weeks. 236 The Pap test using the liquid-based cytology (LBC) sample was performed in all patients every visit 23 at 4 weeks intervals until disease clearance. Confirmation of CIN and VAIN lesion disappearance in 238 colposcopy after Pap test-negative (i.e., negative for intraepithelial lesion or malignancy; NII M) was 239 the definition of disease clearance. We examined cervicovaginal microbiota in the LBC samples 240 before (CIN/VAIN lesion persistence) and after (CIN/VAIN lesion clearance) TCA treatment in this 24 study. 242

### 243 HPV genotyping

HPV-DNA was detected by Uniplex E6/E7 PCR method or GENOSEARCH<sup>™</sup> HPV 31 (Medical & Biological
 Laboratories, Co., Ltd., Tokyo) which can detect up to 39 or 31 HPV genotypes each using LBC

samples (ThinPrep solution, HOLOGIC, Marlborough, MA USA) Okodo et al. (2018). A total of 14

- <sup>247</sup> types including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were classified as high-risk
- <sup>248</sup> HPV genotypes*Campos-Romero et al.* (2019). HPV genotyping was performed for the samples at 1:
- <sup>249</sup> before TCA treatment, 2: after TCA treatment, and 3: follow-up after TCA treatment.

## <sup>250</sup> DNA extraction and 16S ribosomal RNA gene sequencing

LBC samples were sent to Tokai University (Isehara, Japan) for DNA extraction, amplification, and

<sup>252</sup> the 16S ribosomal RNA (rRNA) gene sequencing on an Ion PGM<sup>™</sup> System (Thermo Fisher Scientific,

<sup>253</sup> Waltham, MA USA). The Ion 165<sup>™</sup> Metagenomics Kit was used. Single-end reads were generated for

the seven hypervariable regions (V2, V3, V4, V6, V7, V8, and V9)*Barb et al.* (2016).

### 255 Microbiome analysis

Microbiome bioinformatics was performed with R (version 4.2.1) and OIIME2-2020.11 Bolyen et al. 256 (2019). Hereafter, the abbreviation g2- means OIIME 2 plugins and r- R packages. The Taxonomy 257 database was built using g2-RESCRIPT and SILVA rRNA gene database (SILVA138.1) Robeson et al. 258 (2021)Quast et al. (2012). We removed low-guality sequences, such as those containing five or more 259 ambiguous bases and eight or more homopolymers. We adopted bacteria rRNA gene sequences 260 over 1400 bp to build the taxonomy database Robeson et al. (2021)Yang et al. (2016), Naive-Bayes-261 based taxonomy classifier was created through a2-feature-classifier **Bokulich et al. (2018)Pedregosa** 262 et al. (2011)7iemski et al. (2021) 263

Demultiplexed 20 fasto files for samples before and after chemical peeling by TCA of 10 patients 264 consisting of single-end reads were imported by a2-tools import command and visualized by a2demux summarize. We generated an amplicon sequence variant (ASV) using g2-dada2 Callahan et al. 266 (2016). The g2-dada2 denoised and dereplicated reads and removed chimeras Callahan et al. (2016). 267 Using the option of  $\alpha^2$ -dada2, the reads were trimmed at 15 bp under no truncated and pooled 268 options**Pos** (2023). The ASVs were assigned taxonomy through g2-feature-classifier classify-sklearn 269 using above the Naive-Baves-based taxonomy classifier **Bokulich et al.** (2018). The confidence 270 parameter in g2-feature-classifier classify-sklearn was set as 0.5 to obtain a high-recall**Bokulich** 271 et al. (2018). ASVs classified as Chloroplast, Mitochondria, Eukaryota, Unassigned and those with no 272 phylum-level taxonomic information were removed by a2-taxa filter-table. As final quality filtering. 273 we retained ASVs that had at least 90% identity and 90% guery alignment with the SILVA ribosomal 274 RNA gene database using g2-guality-control. The top 10 abundant taxa at the genus level were 275 displayed in colored bar plots separated as before and after TCA treatment for each positive or 276 negative value of high-risk HPV after TCA treatment McMurdie and Holmes (2013). 277

Species richness called alpha diversity for the difference within the sample was derived using q2 breakaway*Willis and Bunge (2015)*. The changes in alpha diversity before and after TCA treatment
 were plotted for each patient, divided into high-risk HPV positive and negative after TCA treatment.
 A test of similarity called beta diversity of the cervicovaginal microbiome composition pre- or post TCA treatment was evaluated using the q2-diversity adonis*Anderson (2001)* and plotted using the
 principal component analysis.
 As differential abundance analysis for cervicovaginal microbiome before and after TCA treatment.

<sup>284</sup> As differential abundance analysis for cervicovaginal microbiome before and after TCA treatment,
 <sup>285</sup> we compared the abundance of taxa using DESeq2 in r-microbiomeMarker under the following
 <sup>286</sup> parameter setting; normalization method: relative log expression; identity method: Wald; p-value
 <sup>287</sup> adjustment for multiple comparisons: Benjamini-Hochberg; and p-value cutoff: 0.05*Cao et al.* <sup>288</sup> (2022)Love et al. (2014).

### **Acknowledgments**

<sup>290</sup> We would like to thank Editage (www.editage.com) for English language editing. We would like to

<sup>291</sup> thank the Medical Science College Office, Tokai University for technical assistance.

- <sup>292</sup> Financial disclosure
- 293 None reported.
- 294 **Conflict of interest**
- <sup>295</sup> The authors declare no potential conflict of interests.

- **Author contributions**
- <sup>297</sup> To. S. is responsible for the study's conception and design. Ta. S. and To. S. wrote and all authors
- 298 revised the manuscript, Ta, S, conducted the analyses, O, A, and T, J, conducted DNA extraction
- <sup>299</sup> and high-throughput sequencing of DNA. All authors interpreted the data.
- 300 References
- Human papillomavirus (HPV) and cervical cancer; 2021. https://www.who.int/news-room/fact-sheets/detail/ human-papillomavirus-(hpv)-and-cervical-cancer.
- Human Papillomavirus (HPV) Infection 2015 STD Treatment Guidelines; 2021. https://www.cdc.gov/std/tg2015/
  hpv.htm.
- 305 WHO | Human Papillomavirus; 2021. https://www.who.int/ith/diseases/hpv/en/.
- <sup>306</sup> Possible Analysis Pipeline for Ion Torrent 16S Metagenomics Kit Data in QIIME2?; 2023. https://forum.giime2.org.

Anderson MJ. A new method for non-parametric multivariate analysis of variance. Austral ecology. 2001;
 26(1):32–46. doi: https://doi.org/10.1111/j.1442-9993.2001.01070.pp.x.

Barb JJ, Oler AJ, Kim HS, Chalmers N, Wallen GR, Cashion A, Munson PJ, Ames NJ. Development of an analysis
 pipeline characterizing multiple hypervariable regions of 16S rRNA using mock samples. PLoS One. 2016;
 11(2):e0148047.

Bevis KS, Biggio JR. Cervical conization and the risk of preterm delivery. American journal of obstetrics and gynecology. 2011; 205(1):19–27.

Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Caporaso JG. Optimizing taxonomic
 classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome.
 2018; 6(1):1–17.

Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar
 F, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nature
 biotechnology. 2019: 37(8):852–857.

Brotman RM, Shardell MD, Gajer P, Tracy JK, Zenilman JM, Ravel J, Gravitt PE. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. The Journal of infectious diseases.
 2014; 210(11):1723–1733.

Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference
 from Illumina amplicon data. Nature methods. 2016; 13(7):581–583.

Campos-Romero A, Anderson KS, Longatto-Filho A, Esparza MALR, Morán-Portela DJ, Castro-Menéndez JA,
 Moreno-Camacho JL, Calva-Espinosa DY, Acosta-Alfaro MA, Meynard-Meiía FA, et al. The burden of 14 hr-HPV

- genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional
- study. Scientific reports. 2019; 9(1):1–10.

Cao Y, Dong Q, Wang D, Zhang P, Liu Y, Niu C. microbiomeMarker: an R/Bioconductor package for microbiome
 marker identification and visualization. Bioinformatics. 2022; 38(16):4027–4029.

Cha MK, Lee DK, An HM, Lee SW, Shin SH, Kwon JH, Kim KJ, Ha NJ. Antiviral activity of Bifidobacterium adolescentis
 SPM1005-A on human papillomavirus type 16. BMC medicine. 2012; 10:1–6.

Cheng L, Norenhag J, Hu YO, Brusselaers N, Fransson E, Ährlund-Richter A, Guðnadóttir U, Angelidou P, Zha Y,
 Hamsten M, et al. Vaginal microbiota and human papillomavirus infection among young Swedish women.
 NPI biofilms and microbiomes. 2020; 6(1):1–10.

Doocey CM, Finn K, Murphy C, Guinane CM. The impact of the human microbiome in tumorigenesis, cancer
 progression, and biotherapeutic development. BMC microbiology. 2022; 22(1):1–17.

Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease
 association. Reviews in medical virology. 2015; 25:2–23.

Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human
 papillomaviruses. Vaccine. 2012; 30:F55–F70.

- Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer
  M, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30:F12–F23.
- Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer?
  Translational Research. 2017; 179:168–182.
- Lin D, Kouzy R, Abi Jaoude J, Noticewala SS, Delgado Medrano AY, Klopp AH, Taniguchi CM, Colbert LE. Microbiome
  factors in HPV-driven carcinogenesis and cancers. PLoS Pathogens. 2020; 16(6):e1008524.
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.
  Genome biology. 2014; 15(12):1–21.
- Maehama T, Shimada S, Sakamoto J, Shibata T, Fujita S, Takakura M, Takagi H, Sasagawa T. Chemical Peeling
  Therapy Using Phenol for the Cervico-Vaginal Intraepithelial Neoplasia. Viruses. 2023; 15(11):2219.
- McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome
  census data. PloS one. 2013; 8(4):e61217.
- Mei L, Wang T, Chen Y, Wei D, Zhang Y, Cui T, Meng J, Zhang X, Liu Y, Ding L, et al. Dysbiosis of vaginal microbiota associated with persistent high-risk human papilloma virus infection. Journal of translational medicine. 2022; 20(1):1–8.
- Mitra A, MacIntyre DA, Marchesi JR, Lee YS, Bennett PR, Kyrgiou M. The vaginal microbiota, human papillomavirus
  infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome.
  2016; 4(1):1–15.
- Nicolò S, Tanturli M, Mattiuz G, Antonelli A, Baccani I, Bonaiuto C, Baldi S, Nannini G, Menicatti M, Bartolucci G,
  et al. Vaginal lactobacilli and vaginal dysbiosis-associated bacteria differently affect cervical epithelial and
- immune homeostasis and anti-viral defenses. International journal of molecular sciences. 2021; 22(12):6487.
- Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal microbiota, human
  papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG: An International
  Journal of Obstetrics & Gynaecology. 2020; 127(2):171–180.
- Okodo M, Okayama K, Teruya K, Sasagawa T. Uniplex E6/E7 PCR method detecting E6 or E7 genes in 39 human
  papillomavirus types. Journal of Medical Virology. 2018; 90(5):981–988.
- Ou YC, Fu HC, Tseng CW, Wu CH, Tsai CC, Lin H. The influence of probiotics on genital high-risk human papilloma
  virus clearance and quality of cervical smear: a randomized placebo-controlled trial. BMC Women's Health.
  2019; 19(1):1–7.
- Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy.
  Frontiers in microbiology. 2020; 10:3116.
- Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R,
  Dubourg V, et al. Scikit-learn: Machine learning in Python. the Journal of machine Learning research. 2011;
  12:2825–2830.
- Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. The SILVA ribosomal
  RNA gene database project: improved data processing and web-based tools. Nucleic acids research. 2012;
  41(D1):D590–D596.
- Robeson MS, O'Rourke DR, Kaehler BD, Ziemski M, Dillon MR, Foster JT, Bokulich NA. RESCRIPt: Reproducible
  sequence taxonomy reference database management. PLoS computational biology. 2021; 17(11):e1009581.
- Sasagawa T, Inoue M, Inoue H, Yutsudo M, Tanizawa O, Hakura A. Induction of uterine cervical neoplasias in
  mice by human papillomavirus type 16 E6/E7 genes. Cancer research. 1992; 52(16):4420–4426.
- Schwameis R, Ganhoer-Schimboeck J, Hadjari VL, Hefler L, Bergmeister B, Kuessel T, Gittler G, Steindl Schoenhuber T, Grimm C. TRICIN: A Phase II Trial on the Efficacy of Topical TRIchloroacetic Acid in Patients
  with Cervical Intraepithelial Neoplasia. Cancers. 2022: 14(23):5991.
- Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, Gonzalez P, Safaeian M, Schiffman M, Burk RD,
  et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS pathogens. 2020;
  16(3):e1008376.
- Willis A, Bunge J. Estimating diversity via frequency ratios. Biometrics. 2015; 71(4):1042–1049.

- 390 Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: inci-
- dence and risk factors in a cohort of female university students. American journal of epidemiology. 2003; 157(3):218–226.
- Yang B, Wang Y, Qian PY. Sensitivity and correlation of hypervariable regions in 16S rRNA genes in phylogenetic
  analysis. BMC bioinformatics. 2016; 17(1):1–8.
- <sup>395</sup> Ziemski M, Wisanwanichthan T, Bokulich NA, Kaehler BD. Beating naive Bayes at taxonomic classification of
- <sup>396</sup> 16S rRNA gene sequences. Frontiers in Microbiology. 2021; 12:644487.